Septerna, Inc. SEPN 深 沪
等待开盘 01-30 09:30:00 美东时间
23.80
+0.140
+0.59%
华盛通- 最 高24.805
- 今 开23.96
- 成交量 28.65万股
- 最 低 23.665
- 昨 收 23.66
- 总市值 10.60亿
- 52周最高 30.50
- 市盈率 静 --
- 换手率 0.64%
- 52周最低 4.17
- 委 比 -37.50%
- 总股本 4455.83万
- 历史最高 30.50
- 量 比 1.10
- 振 幅 4.82%
- 历史最低 4.17
- 每 手 1
- 风险率 7.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $30 to $35.
01-20 19:53
Septerna Appoints Mark Wilson as Chief Legal Officer
Septerna, Inc. ( ($SEPN) ) has provided an announcement. On January 8, 2026, Se...
01-09 06:04
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna, Inc. announced the appointment of Mark A. Wilson as Chief Legal Officer. With over 25 years of experience in intellectual property, corporate law, and strategic collaborations, Wilson joins from Nektar Therapeutics, where he served as Senior Vice President and Chief Legal Officer. His expertise is expected to strengthen Septerna’s governance and maximize the value of its Native Complex Platform™, which advances GPCR drug discovery. Wils...
01-08 21:05
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Jones Trading Initiates Coverage On Septerna with Buy Rating, Announces Price Target of $43
Jones Trading analyst Catherine Novack initiates coverage on Septerna (NASDAQ:SEPN) with a Buy rating and announces Price Target of $43.
2025-12-23 22:09
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna, Inc., a clinical-stage biotechnology company focused on GPCR drug discovery, announced that CEO Jeffrey Finer, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:45 p.m. PT in San Francisco. The presentation will be webcast live and archived for 30 days on the company’s website. Septerna develops novel oral small molecule drug candidates using its proprietary Native Complex Platform™...
2025-12-17 13:00
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Truist Securities Initiates Coverage On Septerna with Buy Rating, Announces Price Target of $34
Truist Securities analyst Srikripa Devarakonda initiates coverage on Septerna (NASDAQ:SEPN) with a Buy rating and announces Price Target of $34.
2025-12-15 21:52
